STAND

STAND. COM. REP. NO. 689-06

Honolulu, Hawaii

, 2006

RE: H.B. No. 1869

H.D. 1

Honorable Calvin K.Y. Say

Speaker, House of Representatives

Twenty-Third State Legislature

Regular Session of 2006

State of Hawaii

Sir:

Your Committee on Finance, to which was referred H.B. No. 1869, H.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO ADVERTISING BY DRUG MANUFACTURERS AND DISCLOSURE OF CLINICAL TRIALS,"

begs leave to report as follows:

The purpose of this bill is to increase prescription drug safety, as well as the availability of accurate prescription drug information by:

(1) Requiring that prescription drug advertisements meet federal standards;

(2) Mandating that a manufacturer or labeler of prescription drugs post prescription drug clinical trial results on a publicly accessible Internet website;

(3) Requiring prescription drug manufacturers to pay fees to the Department of Health (DOH);

(4) Establishing a Prescription Drug Advertising Special Fund;

(5) Using fees to fund public education initiatives to inform consumers about clinical trials and to provide drug safety information;

(6) Establishing penalties for noncompliance; and

(7) Requiring DOH to submit a report to the Legislature regarding the completeness and ease of public access to information provided by prescription drug manufacturers and the need for any further legislation.

ILWU Local 142 and the Consumers Union testified in support of this bill. DOH and the Pharmaceutical Research and Manufacturers of America opposed this measure.

As affirmed by the record of votes of the members of your Committee on Finance that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 1869, H.D. 1, and recommends that it pass Third Reading.

Respectfully submitted on behalf of the members of the Committee on Finance,

		____________________________ DWIGHT TAKAMINE, Chair